Altimmune (NASDAQ:ALT) Issues Quarterly Earnings Results

Altimmune (NASDAQ:ALT) posted its earnings results on Wednesday. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.07, FiscalAI reports. Altimmune had a negative return on equity of 49.35% and a negative net margin of 214,860.98%.

Here are the key takeaways from Altimmune’s conference call:

• Altimmune said it raised $225 million in an oversubscribed April offering, bringing pro forma cash to about $535 million and funding the company through the expected 2029 Phase III MASH 52-week data readout.
• The company said its global Phase III MASH study, PERFORMA, is on track to start in the second half of 2026, with the protocol finalized and aligned with both the FDA and EMA.
• Management emphasized pemvidutide’s potential differentiation in MASH, pointing to a favorable tolerability profile, simple titration, sustained weight loss, and possible preservation of lean muscle mass versus some competing GLP-1-based therapies.
• Altimmune said the 48-week Phase II IMPACT results will be presented orally at EASL, including additional fibrosis analysis and other biomarker data, which the company said should reinforce interest in the program.
• Beyond MASH, Altimmune remains on track to report Phase II AUD top-line data next quarter and expects to complete enrollment in the ALD RESTORE trial in the third quarter of 2026.

Altimmune Stock Down 1.5%

NASDAQ:ALT traded down $0.05 on Thursday, hitting $2.98. 1,089,582 shares of the company’s stock were exchanged, compared to its average volume of 4,500,375. The firm has a 50-day moving average price of $3.31 and a 200-day moving average price of $4.12. Altimmune has a 52 week low of $2.56 and a 52 week high of $7.73. The company has a debt-to-equity ratio of 0.15, a current ratio of 18.55 and a quick ratio of 18.55. The company has a market cap of $387.05 million, a P/E ratio of -2.95 and a beta of 0.18.

Insider Activity

In related news, CEO Jerome Benedict Durso bought 20,000 shares of the stock in a transaction that occurred on Friday, March 6th. The shares were acquired at an average price of $3.54 per share, with a total value of $70,800.00. Following the completion of the transaction, the chief executive officer owned 32,500 shares in the company, valued at $115,050. The trade was a 160.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 1.60% of the company’s stock.

Institutional Investors Weigh In On Altimmune

A number of institutional investors and hedge funds have recently modified their holdings of the company. Arax Advisory Partners lifted its stake in Altimmune by 99.7% in the 4th quarter. Arax Advisory Partners now owns 8,165 shares of the company’s stock valued at $29,000 after purchasing an additional 4,076 shares during the last quarter. Quadrature Capital Ltd acquired a new position in Altimmune during the fourth quarter worth approximately $36,000. CreativeOne Wealth LLC bought a new stake in Altimmune in the fourth quarter valued at approximately $38,000. Victory Capital Management Inc. acquired a new stake in shares of Altimmune in the third quarter valued at approximately $38,000. Finally, BNP Paribas Financial Markets lifted its position in shares of Altimmune by 108.5% in the second quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company’s stock valued at $39,000 after buying an additional 5,253 shares during the last quarter. 78.05% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on the stock. HC Wainwright boosted their price objective on shares of Altimmune from $12.00 to $25.00 and gave the company a “buy” rating in a research report on Monday, March 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Altimmune in a research note on Friday, March 27th. Truist Financial assumed coverage on Altimmune in a report on Wednesday, March 18th. They issued a “buy” rating and a $12.00 price target on the stock. Citizens Jmp reduced their price objective on Altimmune from $14.00 to $11.00 and set a “market outperform” rating for the company in a research report on Thursday. Finally, William Blair reissued a “market perform” rating on shares of Altimmune in a research report on Thursday, March 5th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $17.50.

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.